Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gastric Ulcers - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Gastric Ulcers - Pipeline Review, H1 2016', provides an overview of the Gastric Ulcers pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers - The report reviews pipeline therapeutics for Gastric Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Gastric Ulcers therapeutics and enlists all their major and minor projects - The report assesses Gastric Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Gastric Ulcers Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Gastric Ulcers Overview 6 Therapeutics Development 7 Pipeline Products for Gastric Ulcers - Overview 7 Gastric Ulcers - Therapeutics under Development by Companies 8 Gastric Ulcers - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Gastric Ulcers - Products under Development by Companies 11 Gastric Ulcers - Companies Involved in Therapeutics Development 12 Astellas Pharma Inc. 12 ChoDang Pharm Co., Ltd. 13 Daewoong Pharmaceutical Co., Ltd. 14 Kukje Pharmaceutical Industry Co., Ltd. 15 PharmaReaserch Products Co., Ltd. 16 Sihuan Pharmaceutical Holdings Group Ltd. 17 Gastric Ulcers - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Combination Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 25 Drug Profiles 27 (ecabet + ranitidine) - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 anaprazole sodium - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ASP-6537 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 DWJ-206 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 KJ-14001 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 PMKS-005 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 PRD-007 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules for Gastric Ulcers - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Gastric Ulcers - Recent Pipeline Updates 35 Gastric Ulcers - Dormant Projects 36 Gastric Ulcers - Discontinued Products 37 Gastric Ulcers - Product Development Milestones 38 Featured News & Press Releases 38 Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 38 Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 39 Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 39 Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 39 Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. 40 Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 41 Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court 41 Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 42 Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals 42 Oct 23, 2001: Prilosec US litigation 42 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for Gastric Ulcers, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Gastric Ulcers - Pipeline by Astellas Pharma Inc., H1 2016 12 Gastric Ulcers - Pipeline by ChoDang Pharm Co., Ltd., H1 2016 13 Gastric Ulcers - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 14 Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H1 2016 15 Gastric Ulcers - Pipeline by PharmaReaserch Products Co., Ltd., H1 2016 16 Gastric Ulcers - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Assessment by Combination Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Gastric Ulcers Therapeutics - Recent Pipeline Updates, H1 2016 35 Gastric Ulcers - Dormant Projects, H1 2016 36 Gastric Ulcers - Discontinued Products, H1 2016 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
